ZymoGenetics
12
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
8.3%
1 terminated/withdrawn out of 12 trials
90.9%
+4.4% vs industry average
33%
4 trials in Phase 3/4
40%
4 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Role: collaborator
The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
Role: collaborator
Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants
Role: lead
Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis
Role: lead
Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis
Role: lead
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Role: lead
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
Role: lead
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
Role: lead
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
Role: lead
Study of Recombinant Human Thrombin for Bleeding During Surgery
Role: lead
Study of Recombinant Human Thrombin for Bleeding During Autologous Skin Grafting
Role: lead
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
Role: lead
All 12 trials loaded